# Molecular Mechanisms of APOL1-Associated Kidney Disease

## TL;DR

This paper reviews how APOL1 gene variants contribute to kidney disease in African Americans and explores potential treatments.

## Contribution

The paper provides a comprehensive molecular framework of APOL1-associated kidney disease mechanisms and translational therapeutic strategies.

## Key findings

- APOL1 risk variants G1 and G2 are strongly linked to non-diabetic kidney diseases in African Americans.
- APOL1 risk variants cause podocyte dysfunction through toxic gain-of-function effects and immune activation.
- APOL1 gene-silencing techniques are proposed as potential therapeutic approaches.

## Abstract

The discovery of apolipoprotein L1 (APOL1) risk polymorphisms has significantly changed our knowledge of kidney disease susceptibility and development in African American populations. Several non-diabetic kidney disorders, such as focal segmental glomerulosclerosis (FSGS), collapsing glomerulopathy, HIV-associated nephropathy (HIVAN), and accelerated chronic kidney disease (CKD) development, are significantly more likely to occur in people with two coding variations, G1 and G2. The significance of context-dependent pathogenic processes is highlighted by the poor penetrance and remarkable phenotypic variety of APOL1-associated kidney disease, despite its substantial impact. This review synthesizes current knowledge of APOL1 biology through a molecular framework, emphasizing gain-of-toxic-function effects of risk variants in podocytes, dysregulated ion fluxes, mitochondrial dysfunction, impaired proteostasis, and activation of innate immune and inflammatory signaling pathways. We describe how the well-recognized “second-hit” paradigm has a biological basis, driven by strong inducibility by interferons and immunological activation, as well as strict basal regulation of APOL1 expression. Lastly, we explore future approaches to precision nephrology and highlight translational advancements, such as APOL1 gene-silencing techniques. This review provides a mechanistic roadmap for translating APOL1 biology into targeted therapeutic strategies by integrating genetics, cell biology, immunology, and systems-level approaches.